These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 9698691)

  • 41. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
    J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Editorial comment on: Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy.
    de Reijke TM
    Eur Urol; 2007 Dec; 52(6):1650-1. PubMed ID: 18074436
    [No Abstract]   [Full Text] [Related]  

  • 45. Hormonal manipulation for rising PSA after radical prostatectomy.
    Bhayani SB; Andriole GL
    Semin Urol Oncol; 1999 Aug; 17(3):148-53. PubMed ID: 10462318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neoadjuvant androgen-deprivation therapy prior to radical prostatectomy: con.
    Paulson DF
    Urology; 1996 Oct; 48(4):539-40. PubMed ID: 8886056
    [No Abstract]   [Full Text] [Related]  

  • 47. Adjuvant endocrine therapy after radical prostatectomy for stage D1 prostate carcinoma.
    Stein A; deKernion JB
    Semin Urol; 1990 Aug; 8(3):184-9. PubMed ID: 2119049
    [No Abstract]   [Full Text] [Related]  

  • 48. The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer.
    Joung JY; Kim JE; Kim SH; Seo HK; Chung J; Park WS; Hong EK; Lee KH
    BMC Urol; 2015 Aug; 15():82. PubMed ID: 26269129
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Choice of treatment for locally advanced prostate cancer.
    Prescrire Int; 2013 Jan; 22(134):22. PubMed ID: 23367681
    [No Abstract]   [Full Text] [Related]  

  • 50. [Prostatic carcinoma].
    Weingärtner K; Gerharz EW; Riedmiller H
    Dtsch Med Wochenschr; 1994 Feb; 119(7):235-43. PubMed ID: 7508847
    [No Abstract]   [Full Text] [Related]  

  • 51. [Cyproterone acetate and cancer of the prostate. Experience in 46 cases].
    Tauveron I; Hermabessière J
    Therapie; 1988 May; 43(3):175-7. PubMed ID: 2971277
    [No Abstract]   [Full Text] [Related]  

  • 52. Total androgen suppression: are there any advantages? The use of combined therapy in the treatment of advanced prostate adenocarcinoma.
    Foote JE; Crawford ED
    Semin Urol; 1988 Nov; 6(4):291-302. PubMed ID: 3068767
    [No Abstract]   [Full Text] [Related]  

  • 53. Androgen deprivation in combination with radical prostatectomy for localized prostate cancer.
    Naito S
    Int J Urol; 2001 Jul; 8(7):S19-21. PubMed ID: 11442672
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostatic malignancy.
    Paulson DF
    J Urol (Paris); 1985; 91(7):401-7. PubMed ID: 4086873
    [No Abstract]   [Full Text] [Related]  

  • 55. NIH Consensus Development Conference. Management of clinically localized prostate cancer.
    Oncology (Williston Park); 1987 Nov; 1(9):46-9, 54. PubMed ID: 3079494
    [No Abstract]   [Full Text] [Related]  

  • 56. Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.
    Sonpavde G; Palapattu GS
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):439-50. PubMed ID: 20214524
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
    Madlung A; Simcock M; Ghadjar P
    Cancer; 2011 Aug; 117(15):3532; author reply 3532-3. PubMed ID: 21287542
    [No Abstract]   [Full Text] [Related]  

  • 58. Role of induction androgen deprivation before radical prostatectomy.
    Soloway MS
    Semin Urol; 1995 May; 13(2):142-7. PubMed ID: 7638472
    [No Abstract]   [Full Text] [Related]  

  • 59. The role of neoadjuvant androgen deprivation prior to radical prostatectomy.
    Fradet Y
    Urol Clin North Am; 1996 Nov; 23(4):575-85. PubMed ID: 8948412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment of progressive, locally advanced prostate carcinoma].
    Niesel T; Breul J; Hartung R
    Urologe A; 1998 Mar; 37(2):145-8. PubMed ID: 9563123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.